Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease
Niklas Mattsson, Emelie Andersson, Shorena Janelidze, Rik Ossenkoppele, Philip S. Insel, Olof Strandberg, Henrik Zetterberg, Howard J. Rosen, Gil D. Rabinovici, Xiyun Chai, Kaj Blennow, Jeffrey L. Dage, Erik Stomrud, Ruben Smith, Sebastian Palmqvist, Oskar Hansson
Abstract
mutations and signs of tau deposition (but without Aβ pathology) had normal CSF P-tau levels. In 5xFAD mice, CSF tau increased when Aβ aggregation started. These results show that Aβ pathology may induce changes in soluble tau release and phosphorylation, which is followed by tau aggregation several years later in humans.
Topics & Concepts
Deposition (geology)DiseasePhosphorylationAlzheimer's diseaseNeuroscienceCancer researchCell biologyChemistryMedicineInternal medicineBiologySedimentPaleontologyAlzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroscience and Neuropharmacology Research